Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Public Health and Preventive Medicine
  4. Vol 3, Issue 3, 2023

Progress in Nucleic Acid Testing and Vaccine Research for the Novel Coronavirus

Download as PDF

DOI: 10.23977/phpm.2023.030310 | Downloads: 26 | Views: 420

Author(s)

Shu Yuqing 1, Li Yajun 2, Jiang Haiyin 3, Luan Yifei 3

Affiliation(s)

1 Hangzhou Medical College, School of Public Health, Hangzhou, Zhejiang, 311399, China
2 The First People's Hospital of Guiyang, Guiyang, Guizhou, 550002, China
3 Hangzhou Medical College, Hangzhou, Zhejiang, 311300, China

Corresponding Author

Luan Yifei

ABSTRACT

Since the outbreak of COVID-19, nucleic acid testing has become a critical means for epidemic control, playing an irreplaceable role in containment. Firstly, testing techniques have evolved from initial real-time fluorescence PCR to advanced high-throughput detection technologies including isothermal nucleic acid amplification, nucleic acid mass spectrometry, and next-generation sequencing. These new techniques have enabled highly efficient nucleic acid detection and significantly shortened turnaround time, with improved sensitivity. However, the stability and accuracy of detection still need improvement, requiring comprehensive optimization in aspects like sample processing and reagent selection.In the meantime, remarkable progress has also been achieved in vaccine development, with multiple COVID-19 vaccines approved for use. Vaccines can be categorized into inactivated vaccines, recombinant protein vaccines, DNA vaccines, mRNA vaccines, and viral vector vaccines based on technological approaches. All these vaccines can induce immune responses to some extent, but protection durability and efficacy against emerging variants remain to be investigated. Optimizing vaccine design to enhance safety and immunogenicity is the current priority.

KEYWORDS

Novel coronavirus pneumonia; progress; nucleic acid testing; vaccine; virus detection

CITE THIS PAPER

Shu Yuqing, Li Yajun, Jiang Haiyin, Luan Yifei, Progress in Nucleic Acid Testing and Vaccine Research for the Novel Coronavirus. MEDS Public Health and Preventive Medicine (2023) Vol. 3: 63-70. DOI: http://dx.doi.org/10.23977/phpm.2023.030310.

REFERENCES

[1] Xin Guo, Sun Rong. Prescription-syndrome relationship in traditional Chinese medicine and pharmacology research progress of Huanglian Jiedu Decoction in treatment of COVID-19 with severe syndrome of dual blaze of qi and nutrient [J]. Chinese Traditional and Herbal Drugs, 2020, 51(11): 3070-3077.
[2] A Wu, Peng Y, Huang B, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV)  Originating in China[J]. Cell Host Microbe, 2020, 27(3): 325-328.
[3] B Bakhshandeh, Jahanafrooz Z, Abbasi A, et al. Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus [J]. Microb Pathog, 2021, 154104831.
[4] Jianming Ou, Lin Xiuquan, Xie Zhonghang, et al. Outcome analysis on suspected cases of COVID-19 in Fujian from Jan.2020 to Feb.2020[J]. Strait Journal of Preventive Medicine, 2020, 26(04): 7-9.
[5] M-J McLaughlin, Fisher M-T, Vadivelu S, et al. A risk-stratified approach toward safely resuming On abot ulinum toxin A injections based on dosing and ambulatory status in pediatric patients with cerebral palsy during the Coronavirus pandemic of 2019 (COVID-19)[J]. J Pediatr Rehabil Med, 2020, 13(3): 273-279.
[6] L Wang, Wang Y, Ye D, et al. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence[J]. Int J Antimicrob Agents, 2020, 55(6): 105948.
[7] Meiyu Li, Lu Mingfang, Li Cuizhi, et al. Analysis on the cardiac features of patients with different clinical types of novel coronavirus disease 2019 [J]. Guangdong Medical Journal, 2020, 41(08): 797-800.
[8] Jing Han, Shi Lixia, Xie Yi, et al. Analysis of risk factors for subsequent infection in patients with COVID-19[J]. Tianjin Medical Journal, 2020, 48(10): 916-919.
[9] S Bauernfeind, Einhauser S, Tydykov L, et al. Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination[J]. Vaccines (Basel), 2022, 10(10).
[10] Xiangjuan Huang, Huang Xiangyan. Application research progress of novel coronavirus detection technology[J]. Shandong Medical Journal, 2022, 62(21): 90-94.
[11] C-R Carpenter, Mudd P-A, West C-P, et al. Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases[J]. Acad Emerg Med, 2020, 27(8): 653-670.
[12] V-M Corman, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR[J]. Euro Surveill, 2020, 25(3).
[13] F-J Pineda, Antoine M-D, Demirev P-A, et al. Microorganism identification by matrix-assisted laser/desorption ionization mass spectrometry and model-derived ribosomal protein biomarkers[J]. Anal Chem, 2003, 75(15): 3817-3822.
[14] Tingting Liu, Xu Jinglin, Guo Zishuo, et al. Advances in nucleic acid detection of human respiratory viruses[J]. Chinese Journal of Virology, 2022, 38(04): 965-973.
[15] Dongxiao Li, Li Yi, Zhu Lin, et al. Comparative analysis of SARS-CoV-2 variants with two high-throughput sequencing platforms[J]. Chinese Journal of Zoonoses, 2022, 38(09): 771-777.
[16] J Li, Lai S, Gao G-F, et al. The emergence, genomic diversity and global spread of SARS-CoV-2[J]. Nature, 2021, 600(7889): 408-418.
[17] J-W Ai, Zhang Y, Zhang H-C, et al. Era of molecular diagnosis for pathogen identification of unexplained pneumonia,  lessons to be learned[J]. Emerg Microbes Infect, 2020, 9(1): 597-600.
[18] L Dai, Gao G-F. Viral targets for vaccines against COVID-19 [J]. Nat Rev Immunol, 2021, 21(2): 73-82.
[19] M-M Silveira, Moreira GMSG, Mendonca M. DNA vaccines against COVID-19: Perspectives and challenges[J]. Life Sci, 2021, 267118919.
[20] A Glasper. The quest to find an effective vaccine for COVID-19[J]. Br J Nurs, 2020, 29(11): 644-646.
[21] N-B Mercado, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques [J]. Nature, 2020, 586(7830): 583-588.
[22] Liao Xiaoyan, Lili Chen. Status of COVID-19 vaccine research[J]. China Biotechnology, 2020, 40(12): 8-17.
[23] S Abd-Elsalam, Noor R-A, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study[J]. J Med Virol, 2021, 93(10): 5833-5838.
[24] CYC Chau, Chow LLW, Sridhar S, et al. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders[J]. Ophthalmol Ther, 2021, 10(2): 201-209.
[25] Liu Wei, Chaojie Yang, Liang Q-U, et al. Evaluation of 10 kits for antibody detection of SARS-CoV-2[J]. Journal of International Pharmaceutical Research, 2020, 47(9): 716-721.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 1927
Visits: 86946

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.